A B S T R A C T The role of the enzyme hepatic triglyceride lipase was investigated in a primate model, the cynomolgus monkey. Antisera produced against human postheparin hepatic lipase fully inhibited cynomolgus monkey posttheparin plasma hepatic triglyceride lipase activity. Lipoprotein lipase activity was not inhibited by this antisera. Hepatic triglyceride lipase activity in liver biopsies was decreased by 65-90% after intravenous infusion of this antisera into the cynomolgus monkey. After a 3-h infusion of the antisera, analytic ultracentrifugation revealed an increase in mass of very low density lipoproteins (Sf 20-400). Very low density lipoprotein triglyceride isolated by isopycnic ultracentrifugation increased by 60-300%. Analytic ultracentrifugation revealed an increase in mass of lipoproteins with flotation greater than Sf 9 (n = 4). The total mass of intermediate density lipoproteins approximately doubled during the 3 h of in vivo enzyme inhibition. While more rapidly floating low density lipoproteins (Sf 9-12) increased, the total mass of low density lipoproteins decreased after infusion of the antibodies. The changes in high density lipoproteins did not differ from those in control experiments.
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In order to determine whether the increases of plasma concentrations of very low density lipoproteins were due to an increase in the rate of synthesis or a decrease in the rate of clearance of these particles, the metabolism of radiolabeled homologous very low density lipoproteins was studied during intravenous infusion of immunoglobulin G prepared from the antisera against hepatic triglyceride lipase (n = 3) or preimmune goat sera (n = 3). Studies performed in the same animals during saline infusion were used as controls for each immunoglobulin infusion. There was a twofold increase in the apparent half-life of the very low density lipoprotein apolipoprotein-B tracer in animals receiving the antibody, consistent with a decreased catabolism of very low density lipoproteins. Concomitantly, the rise in low density lipoprotein apoprotein-B specific activity was markedly delayed. None of these changes were observed during infusion of preimmune immunoglobulin G.
Hepatic triglyceride lipase participates with lipoprotein lipase in the hydrolysis of the lipid in very low density lipoproteins, intermediate density lipoproteins, and the larger low density lipoproteins (Sf 9-12). Thus, hepatic triglyceride lipase appears to function in a parallel role with lipoprotein lipase in the conversion of very low density and intermediate density lipoproteins to low density lipoproteins (Sf 0-9).
INTRODUCTION
Catabolism of circulating triglyceride-rich lipoproteins requires their interaction with lipolytic enzymes available to the plasma space. As a result of this process, chylomicrons are converted to smaller remnant particles before their uptake by the liver (1). Most (3) . The enzyme is available to interact with circulating lipoproteins after its attachment to the hepatic endothelial surface (4) . HTGL is a major component of human postheparin lipolytic activity and, in vitro, has both triglyceride hydrolase (5) and phospholipase A-1 activities (6). Although intact chylomicrons are a poor substrate for this enzyme, HTGL has been shown in vitro to hydrolyze triglyceride in both VLDL and chylomicron remnants (7) . Although no primary genetic defect of HTGL has been reported in humans to date, low levels of HTGL activity are found in chronic liver disease (8) , hypothyroidism (9) , and uremia (10) . Abnormal triglyceride-rich lipoproteins are found in the plasma of patients with each of these conditions.
Experimental evidence for the physiologic role of HTGL has been limited to studies in the rat. Immunological inhibition of HTGL in that animal is associated with an increase in high density lipoprotein (HDL) phospholipids (11) (12) (13) . This has led to the suggestion that HTGL has a role in the conversion of HDL2 to HDL3. In some of these studies, an increase of VLDL triglyceride was noted (12, 13) . However, these experiments did not determine if this increase in VLDL was the result of a decrease in catabolism or an increase in production. In addition, these data may not be applicable to human metabolism, since in rats, most of the circulating VLDL is removed from the plasma without conversion to LDL (14) . In humans, the conversion of IDL to LDL has recently been demonstrated to occur primarily across the splanchnic bed (15) . Thus, an enzyme located in the liver may be involved in a pathway involving VLDL catabolism and LDL production. The cynomolgus monkey is an appropriate animal in which to study the role of HTGL, since monkeys, like humans, convert most VLDL to LDL (16) . They also maintain LDL levels that are comparable to human levels. Experiments were designed to determine the changes in lipoprotein levels and composition that might occur during acute inhibition of HTGL in cynomolgus monkeys. In addition, kinetic studies of the metabolism of VLDL apolipoprotein B (apo-B) were performed to determine whether the alterations in lipoproteins were associated with a change in VLDL catabolism.
METHODS
Animals. Adult cynomolgus monkeys, females (3-4 kg) and males (4-5 kg), were maintained on a chow diet containing 5% fat (Ralston Purina, St. Louis, MO). The animals were fasted for 12-14 h before each study. Monkeys were anesthetized with intramuscular ketamine 10 mg/kg (ParkeDavis Company, Morris Plains, NJ) for liver biopsies or insertion of intravenous catheters. For studies of lipoprotein profiles or lipoprotein turnover the animals were restrained in a monkey chair and allowed to revive from anesthesia.
A total of 11 experimental animals were studied according to three different protocols involving (1) infusion of the antibody in conjunction with serial liver biopsies (n = 3), (2) serial sampling for analysis of lipoproteins by analytical and/ or isopycnic ultracentrifugation (n = 5) and (3) turnover studies using radioactive VLDL (n = 3). An additional 10 animals received a preimmune goat immunoglobulin instead of the antibody. Thev were studied as above and served as controls. None of these 21 animals was used in more than one protocol.
In vitro studies. Postheparin plasma was obtained from normal human volunteers 15 min after intravenous injection of 60 U/kg of heparin (Riker Laboratories, Northridge, CA) and from cynomolgus monkeys 10 min after 100 U/kg of heparin. Human HTGL was partially purified and anti-human HTCL antiserum was produced in a goat as previously reported (17) . In vitro assay of human postheparin plasma demonstrated comparable levels of activity after pretreatment with the antibody or with 50 mM sodium dodecyl sulfate (18) using a gum-arabic stabilized emulsion of tri-(H3)oleoylglycerol (New England Nuclear, Boston, MA). When assayed in postheparin plasma under conditions that inhibit LPL but optimize HTGL activity (pH 8.8, 1 M NaCI) (18) , addition of 1/10 vol of the antisera reduced the lipolytic activity by >90%. This inhibition did not require preincubation or centrifugation of the putative immune complex, suggesting that inactivation of HTGL occurs as a result of binding by the antibody at or near the active site.
To reduce possible nonspecific reactions of goat serum during in vivo experiments, an IgG fraction of the antiserum and of preimmune goat serum was prepared using sodium sulfate precipitation (19) . The IgG was dialyzed against sterile 0.15 M NaCl containing 0.1% EDTA (p11 7.4). The goat IgG (both immune and preimmune) was treated by incubation at 4°C with Sepharose beads containing covalently bound whole monkey plasma (preheparin) to absorb nonspecific reactants. This procedure did not reduce the reactivitv of the antisera against HTGL activity. Before absorption, two lines were seen on double diffusion studies with monkey sera, and these disappeared after this procedure. All IgG preparations were assayed for total protein and in vitro activity against HTGL using an artificial emulsion before their use in the monkeys.
To determine the specificity of the anti-HTGL IgG preparation, a natural substrate was used. The triglyceride in human VLDL was radiolabeled with tri-(H3)oleoylglycerol using the method of Fielding (20) . Human HTGL and LPL wvere partially purified by heparin-Sepharose chromatography (21). These enzyme solutions and cynomolgus monkey postheparin plasma lipase activities were assayed in a 0.5-ml assay mixture containing 0.5 mg human VLDL triglyceride (0.1 jCi/mg), 0.16 M NaCL, 12 .5% bovine serum albumin, and 0.35 M tris-HCl, pli 7.4. Monkey postheparin plasma was also preincubated 30 min at 27°C, 1.0 M NaCL, pH 8.8, to completely inhibit LPL and the remaining HTGL activity wvas then assayed in a solution containing 1.25 M NaCI, 8.3% bovine serum albumin, 0.233 M tris-I-CI, pH 8.8. The VLDL substrate was identical to that used for the assay of human enzyme solutions. The enzyme solutions were mixed with increasing volumes of the IgG prepared from the antisera and were then added to the VLDL solution ( Fig.  1) . The assays were then incubated for 60 min at 27°C. Hydrolyzed free fatty acids were extracted and activity was calculated as previously described (18) . All assays were performed in triplicate.
Liver biopsies. Documentation that intravenous infusion of the antibody produced inhibition of HTGL in hepatic tissue was obtained using percutaneous liver biopsy specimens. The assay was initially developed using a homogenate of cynomolgus monkey liver prepared in buffer containing 0.01 M phosphate (pH 7.4) and 0.15 M NaCl (PBS), and 0.2 U/ml heparin. Lipolytic activity was assayed in aliquots of this homogenate using 0.45 ml of gum arabic emulsion containing 5 ,umol of trioleoylglycerol (10 ACi/ml) as previously described (17) . Protein in the liver homogenate was measured by the method of Lowry et al. (22) Immediately before injection, each preparation of IgG (prepared as described above) was filtered through a 0.45-,um filter (Millipore Corp., Bedford, MA) and centrifuged 2 h at 49,000 rpm in an SW50 rotor to remove aggregates. F1 20) were determined by computerized analysis of data from the schlieren patterns of analytical ultracentrifuge runs at 52,640 rpm of the isolated fraction containing LDL, IDL, and VLDL in a base-line solution of d 1.063 g/ ml and the isolated FlIDL in a solution of d 1.20 g/ml (27) . The flotation rates determined by a "n F°vs. p' technique (28) , are expressed in Svedbergs (10-13 cm S' dyn' g-') and are corrected for concentration dependence and to standard conditionis (T = 260C().
Stuidies of VLDL apo-B kinetics. Four to six female mnonkevs (not used for pre'Vious stuidies) wvere plasmapheresed, and 100-200( ml of plasma were collected into sterile tubes. VLDI, was isolated by ultraceintrifugation at d = 1.006 in an SW 28 rotor at 26,000 rpm, 48 h, 10°C. The \N'LDL. was concenitrated bv a second uiltracenitrifugationt in ani SW 60 rotor at 55,000 rpm for 18 After intravenous injection of radioiodinated VLDL, blood samples (1.5-2.0 nil) were obtained from a separate site at 5, 15, 30 min and 1, 3, 6, and 9 h. The next day, an IgG bolus wvas injected as described above and 30 min later the VLDL containing the alternate iodine tracer (1251 or "31) was injected intravenously. Additional IgG was infused (20 mg/'kg) over the subsequent 3 h. Bloodl wvas obtained as in the study the previous day. All blood samples wvere collected into tubes containinig EDTA (3 mg/ml) aind stored at 4°C after centrifugatioin to renmove cells. A 150-pl aliquot of plasnia w%as set aside for cholesterol and trigly!ceride measurements and 1 ml of plasma was used to isolate VLDL, 1)L, ancl LDL in the 40.3 rotor as described above.
Apo-B specific activity in VLDL and IDI was determined uisiing the method of Le et al. (31) . Samples (0.9 ml) were delipidate(d sequentially with acetone (3 nil) and isopropyl alcohol (3 ml). Antibody activity. The specificity of the inhibition was confirmed by incubation of partially purified hunian HTGIL with anl IgG preparation of the anti-IlHTGL, sera. This completely inhibited lipolytic activity measuredl using radiolabeled triglyceride in hunian VLDL at physiologic plI (7.4) (Fig. 1) . LPI activity was not inhibited by the antibody. Cynomolgus monkev postheparin plasma measured under similar conditions vas inhibited -12% by the IgG (Fig. 1B) . This decrease in activity is approximately that expected resuilting from inhibition of the HTGL activity in the assayed plasma. To inhibit the LPL activity, monkey postheparin plasma was preincubated in 1.0 M NaCl for 30 min and then assayed under optimal conditions for I-ITGI, (19) . The postheparin plasma lipase activity assayed in this manner, which should have contained predominantly HTGL activity, was completely inhibited by the aintibody.
The intravenous bolus of anti-HTGL IgG inhibited the hepatic triglyceride lipase activity in monkey liver biopsies by 65 to 90% (Fig. 2) . The suppression was maintainied for over 3 h by the infusion of the IgG. No change in lipase activitv was found in similar hepatic biopsies obtained from animals receiving either preimmune goat IgG (20 mg/kg) or normal saline.
Lipoprotein inasses. Analytical ultracentrifugation showed a marked rise in total VLDL mass in all animals studied after anti IHTGL IgG (Fig. 3) , with the greatest increase confined to the Sf 20-100 range (Fig.  4 , Table I ). The more rapidly floating VLDL (Sf 100-400) also increased in three of four animals. A consistent increase was also found in the Sf 12-20 lipoproteins (Table I ). The Sf 0-12 fraction (LDL) fell in all animals receiving anti-HTGL IgG. Difference plots from each of these four animals (Fig. 4) showed that this fall was due to a decline in the more dense fraction (Sf 0-9). In contrast, the Sf 9-12 lipoproteins increased in all four animals after inhibition of HTGL. The three control animals showed no increase in VLDL (Fig. 3) and inconisistent changes in IDL and LDL. Analytical trol animals when examined 3 h after IgG infusion (Table III) . There were no other consistent changes in the composition of HDL2 or HDL5. Reflecting the VLDL increase, total plasnia triglyceride values increased in each of the five monkeys receiving anti-HTGL IgG, producing a rise for this lipid of 16-140% (Table IV) . A small fall in total plasma cholesterol was found in both treated and control animals. VLDL apolipoprotein B metabolism. The effects of anti-HTGL IgG infusion on the metabolism of apo-B in VLDL, IDL and LDL were studied by intravenous injection of radiolabeled VLDL. As a representative experiment, the specific activities of apo-B in all three lipoproteins from monkeys E9 and C8 during 6 h of saline infusion are shown in the first panel of Figs. 5A and 5B, respectively. In six monkeys studied, the specific activity of apo-B in IDL and LDL rose rapidly, reaching a peak within the first hour during these baseline experiments with saline infusion (Table V) . The metabolism of a second VLDL tracer, which was injected into monkey E-9 during infusion of anti-HTGL IgG, is also shown in Fig. 5A (right panel) . In this and two additional experiments, (monkeys E-10 and E-11), the VLDL apo-B specific activity fell more slowly during the inhibition of HTGL (Table V) . After the antibody infusion, the increase to peak specific activity in IDL was markedly retarded reaching a maximum at -3 h. The peak specific activity for LDL was observed between 3 and 6 h. In the three control experiments (monkeys C-8, C-9, and C-10) nonimmune IgG was infused. No The data from the analytical ultracentrifuge suggest that HTGL may be involved in the conversion of a larger and less dense LDL to the more common Sf 0-9 LDL. Such a role for HTGL is also compatible with a number of clinical observations. Women have lower mean HTGL levels (32) and larger quantities of the more rapidly floating LDL than do men (33) . An increase in light LDL is inversely correlated with HTGL activity as measured in the postheparin plasma of distance runners (34) .
Inhibition of Hepatic Triglyceride Lipase
HDL2 phospholipids and total mass increased in both the experimental and control animals. The lack of clear changes in HDL may relate to the acute nature of these experiments. Similar experiments performed in rats have demonstrated a rise in HDL phospholipids (11) (12) (13) that was confined to the HDL2 density range. In one of these studies (13) , an increase in VLDL clearly preceded the changes in HDL. HTGL has been postulated to be the principal enzyme removing phospholipid from HDL2, thus converting those particles to the more dense HDL3. In view of the present findings, it is possible that the changes observed in the rat may have been secondary to altered metabolism of the lower density lipoproteins. We postulate that during degradation of triglyceride-rich lipoproteins by HTGL, surface components may be directly taken up by the liver. This process could involve apolipoprotein E, a component of VLDL, for which there is a specific receptor on the hepatocyte (35, 36) . By contrast, surface components released by LPL in peripheral tissues may be transferred to HDL (37 LPL may be most active with chylomicrons and larger VLDL that are rich in C apolipoproteins, whereas HTGL may be particularly important in the catabolism of particles that are deficient in the C apolipoproteins (including apolipoprotein CII, the activator of LPL). Compatible with this hypothesis, are the recent reports of reduced hepatic metabolism of VLDL and other triglyceride-rich lipoproteins after addition of a source of C apolipoproteins (38, 39) . Although LPL can convert VLDL to LDL in vitro (40) , this degradative process may be heavily shared with HTGL in vivo. Such a parallel role for HTGL is consistent with the continued metabolism of VLDL and the production of some LDL by human subjects with primary lipoprotein lipase deficiency (41) (42) (43) .
